Andrew Jabbour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Andrew Jabbour has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
Anne M. Keogh
Heart and Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia; UNSW, School of Clinical Medicine, Sydney
3 shared publicationsChris Anthony
The Alfred Health, Melbourne, Australia; Monash Alfred Baker Centre for Cardiovascular Research, Melbourne, Australia
3 shared publicationsEugene Kotlyar
Heart and Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia
3 shared publicationsRobert M. Graham
Victor Chang Cardiac Research Institute, Sydney, Australia; UNSW, School of Clinical Medicine, Sydney
3 shared publicationsCameron Holloway
Heart and Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia
2 shared publicationsChristopher S. Hayward
Heart and Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia; UNSW, School of Clinical Medicine, Sydney
2 shared publications
Latest Publications
- Open Access
- 19 March 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (9) , e2190-e2192
Quantification of left and right atrial late gadolinium enhancement using different methods in healthy individuals
- 19 March 2026
- Published by Elsevier in Heart Rhythm
- Vol. 23 (9) , e2190-e2192
Open AccessQuantification of left and right atrial late gadolinium enhancement using different methods in healthy individuals
- Open Access
- 24 December 2025
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 28 (1) , 102675
Cardiovascular magnetic resonance feature tracking for rejection surveillance after cardiac transplantation
- 24 December 2025
- Published by Elsevier in Journal of Cardiovascular Magnetic Resonance
- Vol. 28 (1) , 102675
Open AccessCardiovascular magnetic resonance feature tracking for rejection surveillance after cardiac transplantation
- 11 April 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (8) , 1173-1183
Cost-Effectiveness of Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation in the Australian Health Care System
- 11 April 2024
- Published by Elsevier in Heart, Lung and Circulation
- Vol. 33 (8) , 1173-1183
Cost-Effectiveness of Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation in the Australian Health Care System
- Open Access
- 1 June 2021
- Published by Elsevier in International Journal of Cardiology Hypertension
- Vol. 9, 100087
Ageing, hypertension and aortic valve stenosis – Understanding the series circuit using cardiac magnetic resonance and applanation tonometry
- 1 June 2021
- Published by Elsevier in International Journal of Cardiology Hypertension
- Vol. 9, 100087
Open AccessAgeing, hypertension and aortic valve stenosis – Understanding the series circuit using cardiac magnetic resonance and applanation tonometry
- 1 April 2021
- Published by Elsevier in JACC: Heart Failure
- Vol. 9 (4) , 301-313
Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)
- 1 April 2021
- Published by Elsevier in JACC: Heart Failure
- Vol. 9 (4) , 301-313
Everolimus for the Prevention of Calcineurin-Inhibitor-Induced Left Ventricular Hypertrophy After Heart Transplantation (RADTAC Study)
- Open Access
- 12 October 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (10) , e0205850
Functional recovery after dantrolene-supplementation of cold stored hearts using an ex vivo isolated working rat heart model
The ryanodine receptor antagonist dantrolene inhibits calcium release from the sarcoplasmic reticulum and reduces cardiac ischaemia-reperfusion injury (IRI) in global warm ischaemia models however the cardioprotective potential of dantrolene under hypothermic conditions is unknown. This study addresses whether the addition of dantrolene during cardioplegia and hypothermic storage of the donor heart can improve functional recovery and reduce IRI. Using an ex vivo isolated working heart model, Wistar rat (3 month and 12 month) hearts were perfused to acquire baseline haemodynamic measurements of aortic flow, coronary flow, cardiac output, pulse pressure and heart rate. Hearts were arrested and stored in Celsior preservation solution supplemented with 0.2–40 μM dantrolene for 6 hours at 4°C, then reperfused (15 min Langendorff, 30 min working mode). In 3-month hearts, supplementation with 1 μM dantrolene significantly improved aortic flow and cardiac output compared to unsupplemented controls however lactate dehydrogenase (LDH) release and contraction bands were comparable. In contrast, 40 μM dantrolene-supplementation yielded poor cardiac recovery, increased post-reperfusion LDH but reduced contraction bands. All 3-month hearts stored in dantrolene displayed significantly reduced cleaved-caspase 3 intensities compared to controls. Analysis of cardioprotective signalling pathways showed no changes in AMPKα however dantrolene increased STAT3 and ERK1/2 signaling in a manner unrelated to functional recovery and AKT activity was reduced in 1 μM dantrolene-stored hearts. In contrast to 3-month hearts, no significant improvements were observed in the functional recovery of 12-month hearts following prolonged storage in 1 μM dantrolene. Conclusions: Dantrolene supplementation at 1 μM during hypothermic heart preservation improved functional recovery of young, but not older (12 month) hearts. Although the molecular mechanisms responsible for dantrolene-mediated cardioprotection are unclear, our studies show no correlation between improved functional recovery and SAFE and RISK pathway activation.
- 12 October 2018
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 13 (10) , e0205850
Open AccessFunctional recovery after dantrolene-supplementation of cold stored hearts using an ex vivo isolated working rat heart model
The ryanodine receptor antagonist dantrolene inhibits calcium release from the sarcoplasmic reticulum and reduces cardiac ischaemia-reperfusion injury (IRI) in global warm ischaemia models however the cardioprotective potential of dantrolene under hypothermic conditions is unknown. This study addresses whether the addition of dantrolene during cardioplegia and hypothermic storage of the donor heart can improve functional recovery and reduce IRI. Using an ex vivo isolated working heart model, Wistar rat (3 month and 12 month) hearts were perfused to acquire baseline haemodynamic measurements of aortic flow, coronary flow, cardiac output, pulse pressure and heart rate. Hearts were arrested and stored in Celsior preservation solution supplemented with 0.2–40 μM dantrolene for 6 hours at 4°C, then reperfused (15 min Langendorff, 30 min working mode). In 3-month hearts, supplementation with 1 μM dantrolene significantly improved aortic flow and cardiac output compared to unsupplemented controls however lactate dehydrogenase (LDH) release and contraction bands were comparable. In contrast, 40 μM dantrolene-supplementation yielded poor cardiac recovery, increased post-reperfusion LDH but reduced contraction bands. All 3-month hearts stored in dantrolene displayed significantly reduced cleaved-caspase 3 intensities compared to controls. Analysis of cardioprotective signalling pathways showed no changes in AMPKα however dantrolene increased STAT3 and ERK1/2 signaling in a manner unrelated to functional recovery and AKT activity was reduced in 1 μM dantrolene-stored hearts. In contrast to 3-month hearts, no significant improvements were observed in the functional recovery of 12-month hearts following prolonged storage in 1 μM dantrolene. Conclusions: Dantrolene supplementation at 1 μM during hypothermic heart preservation improved functional recovery of young, but not older (12 month) hearts. Although the molecular mechanisms responsible for dantrolene-mediated cardioprotection are unclear, our studies show no correlation between improved functional recovery and SAFE and RISK pathway activation.